Purinergic Signalling: Therapeutic Developments
Top Cited Papers
Open Access
- 25 September 2017
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 8, 661
Abstract
Purinergic signalling, i.e., the role of nucleotides as extracellular signalling molecules, was proposed in 1972. However, this concept was not well accepted until the early 1990’s when receptor subtypes for purines and pyrimidines were cloned and characterised, which includes four subtypes of the P1 (adenosine) receptor, seven subtypes of P2X ion channel receptors and 8 subtypes of the P2Y G protein-coupled receptor. Early studies were largely concerned with the physiology, pharmacology and biochemistry of purinergic signalling. More recently, the focus has been on the pathophysiology and therapeutic potential. There was early recognition of the use of P1 receptor agonists for the treatment of supraventricular tachycardia and A2A receptor antagonists are promising for the treatment of Parkinson’s disease. Clopidogrel, a P2Y12 antagonist, is widely used for the treatment of thrombosis and stroke, blocking P2Y12 receptor-mediated platelet aggregation. Diquafosol, a long acting P2Y2 receptor agonist, is being used for the treatment of dry eye. P2X3 receptor antagonists have been developed that are orally bioavailable and stable in vivo and are currently in clinical trials for the treatment of chronic cough, bladder incontinence, visceral pain and hypertension. Antagonists to P2X7 receptors are being investigated for the treatment of inflammatory disorders, including neurodegenerative diseases. Other investigations are in progress for the use of purinergic agents for the treatment of osteoporosis, myocardial infarction, irritable bowel syndrome, epilepsy, atherosclerosis, depression, autism, diabetes, and cancer.Keywords
This publication has 899 references indexed in Scilit:
- P2Y1 receptor activation by photolysis of caged ATP enhances neuronal network activity in the developing olfactory bulbPurinergic Signalling, 2011
- Liver damage and systemic inflammatory responses are exacerbated by the genetic deletion of CD39 in total hepatic ischemiaPurinergic Signalling, 2011
- Effects of diadenosine tetraphosphate on FGF9-induced chloride flux changes in achondroplastic chondrocytesPurinergic Signalling, 2011
- Nucleotide receptors as targets in the pharmacological enhancement of dermal wound healingPurinergic Signalling, 2011
- European meeting “P2 receptors: new targets for the treatment of osteoporosis”Purinergic Signalling, 2011
- The effects of P2X7 receptor antagonists on the formation and function of human osteoclasts in vitroPurinergic Signalling, 2010
- Adenosine in fibrosisModern Rheumatology, 2009
- P2X7 receptor expression is decreased in epithelial cancer cells of ectodermal, uro-genital sinus, and distal paramesonephric duct originPurinergic Signalling, 2009
- An in vivo model of melanoma: treatment with ATPPurinergic Signalling, 2009
- APT102, a novel adpase, cooperates with aspirin to disrupt bone metastasis in miceJournal of Cellular Biochemistry, 2008